The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and ...

The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and ...

LoQus23 Therapeutics, based at Granta Park in Cambridge, has stepped up its bid to combat Huntington’s Disease (HD). It has ...

LoQus23 Therapeutics Ltd ("LoQus23"), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington's Disease ...

The preventive immunization Nous-209 works in an initial trial with patients who have 17 times the risk of developing tumors ...

Colorectal cancer breaks the usual immune rules, with certain regulatory T cells linked to improved survival. In many solid tumors, having a large number of regulatory T (Treg) cells is linked to ...

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T ...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a ...

Scientists are making inroads in understanding one of the central mysteries of human reproduction: Why do women’s eggs ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...